{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T21:00:04Z","timestamp":1761339604634,"version":"3.41.0"},"reference-count":26,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":3112,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS spectr."],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Lamotrigine is approved by the Food and Drug Administration for maintenance therapy in patients with bipolar I disorder. However, several studies of acute-phase and maintenance treatment support the efficacy of lamotrigine for bipolar I and bipolar II disorders. This chart review was performed to assess the efficacy and safety of lamotrigine in the treatment of bipolar disorder in a private psychiatric practice setting and to investigate differences in response among patients with different diagnostic subtypes of bipolar disorder.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The charts of 587 adult outpatients with a primary diagnosis of bipolar disorder who received treatment with lamotrigine in a private practice setting between July 1998 and May 2004 were reviewed retrospectively. Treatment response was assessed with the Clinical Global Impression-Improvement scale and was defined as achievement of a score of \u22642.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three hundred forty-nine patients (59.5%) responded to lamotrigine. Response rates were comparable among patients wit h bipolar I disorder, bipolar II disorder, bipolar disorder not otherwise specified, and among patients with bipolar I disorder who presented with depressive, manic, or mixed episodes. Nonserious rash (12.8%) and headache (2.9%) were the most frequently reported adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results suggest that lamotrigine is effective and well-tolerated in the treatment of bipolar disorder across the spectrum of sub-types of the illness.<\/jats:p><\/jats:sec>","DOI":"10.1017\/s1092852900014504","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T04:48:27Z","timestamp":1470113307000},"page":"376-382","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Lamotrigine for Adults with Bipolar Disorder in a Private Practice Setting"],"prefix":"10.1017","volume":"11","author":[{"given":"Lawrence D.","family":"Ginsberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900014504_ref022","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200012000-00004"},{"key":"S1092852900014504_ref014","doi-asserted-by":"publisher","DOI":"10.3109\/10401230009147081"},{"key":"S1092852900014504_ref006","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.57.5.481"},{"key":"S1092852900014504_ref017","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0321"},{"key":"S1092852900014504_ref015","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.4.392"},{"key":"S1092852900014504_ref016","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0906"},{"key":"S1092852900014504_ref025","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.3.261"},{"key":"S1092852900014504_ref002","doi-asserted-by":"publisher","DOI":"10.1185\/030079903125002801"},{"key":"S1092852900014504_ref026","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2004.00137.x"},{"volume-title":"Manic-Depressive Illness","year":"1990","author":"Goodwin","key":"S1092852900014504_ref003"},{"key":"S1092852900014504_ref005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1684\/j.1950-6945.2004.tb00053.x","article-title":"Antiepileptic drugs: indications other than epilepsy","volume":"6","author":"Spina","year":"2004","journal-title":"Epileptic Disord"},{"key":"S1092852900014504_ref009","unstructured":"Depakote [package insert]. North Chicago, Ill: Abbott Laboratories; 2004."},{"key":"S1092852900014504_ref019","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n1106"},{"key":"S1092852900014504_ref020","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1176\/ajp.156.7.1019","article-title":"Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder","volume":"156","author":"Calabrese","year":"1999","journal-title":"Am J Psychiatry"},{"key":"S1092852900014504_ref007","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0405"},{"key":"S1092852900014504_ref001","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.2.115"},{"key":"S1092852900014504_ref004","first-page":"28","article-title":"Newer anticonvulsants in the treatment of bipolar disorder","volume":"65","author":"Yatham","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"S1092852900014504_ref008","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n0308"},{"key":"S1092852900014504_ref010","unstructured":"Equetro [package insert]. Wayne, Penn: Shire US, Inc; 2004."},{"key":"S1092852900014504_ref011","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216050-00002"},{"key":"S1092852900014504_ref012","unstructured":"Lamictal [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2004."},{"key":"S1092852900014504_ref013","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v60n0203"},{"volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994","key":"S1092852900014504_ref021"},{"key":"S1092852900014504_ref018","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n0210"},{"key":"S1092852900014504_ref023","first-page":"567","volume-title":"The American Psychiatric Publishing Textbook of Psychopharmacology","author":"Bowden","year":"2004"},{"key":"S1092852900014504_ref024","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.6.530"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900014504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T10:57:51Z","timestamp":1749034671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900014504\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S1092852900014504"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900014504","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"type":"print","value":"1092-8529"},{"type":"electronic","value":"2165-6509"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}